Baxter International is selling its biopharma solutions business to private equity firms. The transaction is part of a broader trend in which life science firms are spinning out or selling operations in order to hone the focus of the remaining business on certain areas.
An Aptinyx Parkinson’s disease drug candidate failed to beat a placebo—the biotech’s third mid-stage failure in the past year. Aptinyx is now terminating a separate PTSD program, cutting costs, and exploring “strategic alternatives.”
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
AbbVie acquired DJS Antibodies for $255 million up front. The U.K.-based biotech’s lead program is an antibody drug in preclinical development for idiopathic pulmonary fibrosis, a chronic lung disorder with few FDA-approved treatments.
AbbVie drug Skyrizi is now approved for Crohn’s disease, making it the first treatment for the disorder that addresses a particular protein associated with inflammation. In other drug decision news, the Rhythm Pharmaceuticals product Imcivree added the rare disease Bardet-Beidl syndrome as a new approved indication.
AbbVie drug Quilpta, developed specifically for migraine prevention, is now FDA approved, the latest product in a new class of migraine medicines. The AbbVie drug is the second oral migraine prevention drug that the FDA has approved this year.
AbbVie will take the lead on commercializing Regenxbio’s gene therapy in wet AMD and diabetic retinopathy. It’s AbbVie’s second major gene therapy deal this year, coming months after it committed $90 million to preclinical-stage Capsida Biotherapeutics.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
AbbVie is acquiring a Teneobio subsidiary developing a drug that targets BCMA, a popular protein target for multiple myeloma drugs. There are two FDA-approved BCMA-targeting therapies and more on the way, but AbbVie believes the newest addition to its pipeline could offer some advantages.
As part of its ongoing effort to improve maternal outcomes in the country, the government has approved Illinois' request to extend full Medicaid coverage for new mothers. The approval extends the coverage from 60 days to one year and will give about 2,500 women living below the poverty line access to care every year.
The drugmaker said Friday that it would partner with Shanghai-based I-Mab on the development of lemzoparlimab, a drug that targets CD47. The antigen target, also known as the "don't eat me" signal, is a growing area of immunotherapy, as illustrated by Gilead's $4.9 billion buyout of Forty Seven in March.
The Chicago-based startup company plans to use the funding to further growth of its product offering and integration with EHRs and genetic testing partners.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
"Everybody's an infectious disease company now," ARCH Venture Partners Managing Director Bob Nelsen said. By contrast, a report last year showed a huge decline in venture capital investment in the infectious disease space.
The deal, which includes a hefty $750 million upfront payment to Genmab, focuses on bispecific antibodies and also a drug discovery research partnership.
NPR reported on the study by The Cleveland Clinic's Dr. Gary Procop, which has not been peer reviewed. Procop acknowledged that he had stored samples in a special solution not recommended by the company, which defended the ID NOW test.
The diagnostics company said it had received the EUA for use of its ID NOW system, which can detect a positive result in as low as five minutes and a negative result in 13 minutes. ID NOW is mainly used in urgent care settings.
The companies said Venclexta extended overall survival in untreated acute myeloid leukemia patients when combined with Bristol-Myers Squibb's Vidaza. A prior Phase III confirmatory trial, combining the drug with low-dose cytarabine, failed.